Clinical Trials Logo

Clinical Trial Summary

To investigate the regression model of positive nodes after neoadjuvant chemotherapy (NAC) by injecting and tracing carbon nanoparticles (CNs) in fusion node prior to NAC in patients with breast cancer.

Clinical Trial Description

Approximate 20% of breast cancer survivors develop cancer-related arm lymphedema (BCRAL) which causes substantial functional impairment and psychological morbidity with no effective treatment. While the etiology of BCRL is complicated, the findings of a meta-analysis reviewing 72 studies demonstrated that axillary lymph node dissection (ALND), more extensive breast surgery, radiotherapy, chemotherapy, being overweight or obese and physical inactivity were consistently associated with increased BCRAL risk. One of the primary factors, the extent of ALND is positively correlated with BCRAL. Over the past 20 years, the increasing number of patients with early-stage breast cancer can avoid the risk of arm lymphedema caused by ALND in cases where the sentinel lymph nodes (SLNs) are negative for cancer cell. Sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) is a feasible and accurate tool in patients with operable T1-3, N1 and clinically node-negative breast cancer after therapy. Some studies, however, regarded the false negative rate (FNR) of 14% for SLNB after NAC as unacceptable when compared with the below 5% rate produced by the pioneers of SLNB. The placement of clips at the diagnosis of node-positive disease with removal of the clipped nodes during SLNB reduces the false negative rate FNR after NAC. Additionally, about 9% patients with positive node and T0-2 breast cancer have residual positive node in level III region after NAC. Therefore, it is essential to explore the regression model post NAC in patients who are node positive prior to NAC. Carbon nanoparticles (CNs) suspension contains nanosized polymeric carbon granules with an average diameter of 150 nm and ensures the passing of CNs through the lymphatic vessels (diameter 120-500 nm) rather than blood capillaries (diameter 20-50 nm) due to their molecular size. In the present study, CNs suspension was injected into fusion nodes guided by ultrasound in patients with advanced breast cancer before NAC, total ALND (from level I to III) and breast surgery were then performed after NAC. The distribution of CNs traced in axillary nodes was investigated to establish the regression model of positive nodes in relation to NAC. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03355261
Study type Interventional
Source Shengjing Hospital
Contact Jianyi Li, Master
Phone 8618940257177
Status Recruiting
Phase N/A
Start date May 1, 2014
Completion date May 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03591848 - Pilote Study of an Online Decision Support Tool for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03095352 - A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Phase 2
Active, not recruiting NCT01472094 - Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer Phase 2
Recruiting NCT03709134 - Genomic Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment
Recruiting NCT03667716 - COM701 in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT02894398 - Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant Phase 2
Active, not recruiting NCT01857193 - Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Phase 1
Recruiting NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Recruiting NCT03432429 - REI-EXCISE iKnife Study N/A
Active, not recruiting NCT02139358 - Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Recruiting NCT03615573 - Survey Study: Financial Impact of Breast Cancer Treatment
Completed NCT03323333 - Psychosocial Intervention Pilot for Partners in BRCA Testing N/A
Terminated NCT01649258 - Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy Phase 1
Withdrawn NCT03285607 - MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT01992432 - Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A